NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

May 31, 2023

Study Completion Date

December 19, 2025

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAtypical Chronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaEssential ThrombocythemiaMyelodysplastic/Myeloproliferative NeoplasmMyelofibrosisPolycythemia VeraRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Carboplatin

Given IV

DRUG

Topotecan

Given IV

DRUG

Topotecan Hydrochloride

Given IV

DRUG

Veliparib

Given PO

Trial Locations (6)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

92663

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH